Neurocrine Bio. stock price target raised to $169 by Jefferies
PositiveFinancial Markets

Neurocrine Biosciences has received a boost as Jefferies has raised its stock price target to $169. This adjustment reflects growing confidence in the company's potential and could attract more investors. Such positive analyst ratings often lead to increased market interest, which is crucial for the company's growth and stability in the competitive biotech sector.
— Curated by the World Pulse Now AI Editorial System